Trial · NCT00552240
Registered outcomes48
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 48
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Virologic Response (VR) | baseline to week 48 | VR is defined as HIV viral load of \<50 copies/ml measured at two consecutive visits PRIOR TO Week 48 and without subsequent rebound or change of ARV therapy prior to Week 48. |
| Secondary | Number of Participants With Virologic Response According to the Time to Loss of Virologic Response (TLOVR) Algorithm | baseline to week 48 | HIV viral load \<50 copies/ml measured at two consecutive visits UP TO Week 48 and without subsequent rebound or change of ARV therapy up to Week 48. |
| Secondary | Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48 | baseline to week 48 | HIV viral load \<50 copies/ml measured at Week 48 among observed cases on-treatment. |
| Secondary | Number of Participants With Virologic Success (FDA Definition) | baseline to week 48 | HIV viral load \<50 copies/ml measured in the Week 48 window whereby patients withdrawing early and patients without a Week 48 assessment are considered failures. Includes all participants in full analysis set (FAS). |
| Secondary | Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants | baseline to week 48 | Time to response whereby patients withdrawing early were censored after their withdrawal |
| Secondary | Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml | baseline to week 48 | |
| Secondary | Number of Participants With Loss of Virologic Response Following Confirmed Virologic Response | baseline to week 24 and week 48 | HIV viral load \> 50 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values \< 50 copies/ml) |
| Secondary | Number of Participants With HIV Viral Load < 50 Copies/ml at Week 2 of Treatment | baseline to week 2 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 50 Copies/ml at Week 4 of Treatment | baseline to week 4 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 50 Copies/ml at Week 6 of Treatment | baseline to week 6 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 50 Copies/ml at Week 8 of Treatment | baseline to week 8 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 50 Copies/ml at Week 12 of Treatment | baseline to week 12 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 50 Copies/ml at Week 24 of Treatment | baseline to week 24 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 50 Copies/ml at Week 36 of Treatment | baseline to week 36 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48 of Treatment | baseline to week 48 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 400 Copies/ml at Week 2 of Treatment | baseline to week 2 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 400 Copies/ml at Week 4 of Treatment | baseline to week 4 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 400 Copies/ml at Week 6 of Treatment | baseline to week 6 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 400 Copies/ml at Week 8 of Treatment | baseline to week 8 | Results within time windows, patients on-treatment |
| Secondary | Number of Participants With HIV Viral Load < 400 Copies/ml at Week 12 of Treatment | baseline to week 12 | Results within time windows, patients on-treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00552240/registered